Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen

NEW YORK, April 1, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Gilead Sciences, Inc. Analyst Notes 

On March 27, 2014, Gilead Sciences, Inc. (Gilead) announced that its Marketing Authorization Application (MAA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection has been fully validated and is currently under assessment by the European Medicines Agency (EMA). "Based on the results of the Phase 3 ION studies, LDV/SOF has the potential to transform HCV therapy for genotype 1 patients by eliminating the need for interferon injections and ribavirin and reducing the duration of treatment," said Norbert Bischofberger, PhD, Executive Vice President of Research and Development and Chief Scientific Officer at Gilead. "If approved, LDV/SOF would be the first all-oral treatment option that has the potential to cure HCV in as little as eight weeks." The full analyst notes on Gilead Sciences, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/GILD/report.pdf

--

Enzymotec Ltd. Analyst Notes 

On March 5, 2014, Enzymotec Ltd. (Enzymotec) announced the closing of a registered public offering by certain selling shareholders of 5.4 million ordinary shares at $28.00 per share, including 0.7 million shares purchased pursuant to the full exercise of the underwriters' option to purchase additional shares. The Company noted that it did not receive any proceeds from the sale of these shares. The full analyst notes on Enzymotec Ltd. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/ENZY/report.pdf

--

Intrexon Corporation Analyst Notes 

On March 27, 2014, Intrexon Corporation (Intrexon) announced the formation of Intrexon Energy Partners (IEP), a joint venture with a select group of external investors. The Company noted that IEP aims to optimize and scale-up Intrexon's gas-to-liquid (GTL) bioconversion platform for the production of fuels and lubricants. The Company further explained that IEP's first target product is isobutanol for gasoline blending. "As our first partnered endeavor in the Energy Sector, the formation of IEP exemplifies investor confidence in the power of our integrated synthetic biology platforms beyond our established health, food, and consumer capabilities," said Randal J. Kirk, Chairman and CEO of Intrexon. "We envision IEP building upon Intrexon's biocatalyst platform to produce additional high-value fuels and lubricants beyond isobutanol." The full analyst notes on Intrexon Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04012014/XON/report.pdf

--

Advaxis, Inc. Analyst Notes 

On March 24, 2014, Advaxis, Inc. (Advaxis) announced the appointment of Sara Bonstein to the position of CFO and Senior Vice President. Prior to joining the Company, Bonstein worked at Eli Lilly & Company. "Sara's significant financial experience across multiple biopharmaceutical sectors will be a great asset to Advaxis," said Daniel J. O'Connor, President and CEO of Advaxis. O'Connor added, "She is a seasoned financial leader in the biopharmaceutical industry and, importantly, has demonstrated the ability to lead budget and forecast activities for clinical R&D and manufacturing, which is crucial to our growth. She has been successful in building and managing world class finance teams at significant public biopharmaceutical corporations. Sara's strong operational experience in systems development, budget, forecasting, clinical, and regulatory affairs will be invaluable as we continue to grow Advaxis." The full analyst notes on Advaxis, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/ADXS/report.pdf

--

Repligen Corporation Analyst Notes 

On March 26, 2014, Repligen Corporation (Repligen) announced the commercial launch of its OPUS® 45 cm diameter columns (OPUS 45) with the largest capacity currently available on the market. The Company noted that OPUS 45 aims to process large single-use bioreactor harvests. "Since launching process scale OPUS columns in 2012, our biopharmaceutical customers have embraced our "any resin, any size" approach which offers the most flexibility among run-ready chromatography options," said Steve Tingley, Vice President of Bioprocessing Sales & Marketing for Repligen. "Since then, our customers have requested OPUS columns that are capable of processing harvests from larger disposable fermentors for producing clinical-stage drug candidates and niche commercial biologics. In response we are introducing OPUS 45 and have already begun to fulfill orders." The full analyst notes on Repligen Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04012014/RGEN/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review